Valneva SE reported positive four-year antibody persistence data for its chikungunya vaccine, IXCHIQ. Among 254 healthy adults monitored, 95% maintained high antibody levels four years post-vaccination. Older adults showed similar immune responses to younger adults. Trial VLA1553-303 also found no safety concerns over two years, with no ongoing adverse events. Antibody persistence will continue to be monitored for up to ten years. This news showcases the long-lasting effectiveness and safety of Valneva’s chikungunya vaccine, providing hope in the fight against the disease.

Read more at Nasdaq, Inc.: Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ